Verastem Oncology (NASDAQ: VSTM) reported Q2 EPS of ($0.31), $0.12 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $40.07 million versus the consensus estimate of $23.09 million.

For earnings history and earnings-related data on Verastem Oncology (VSTM) click here.